Literature DB >> 31658057

Association of Cardiovascular and Alzheimer's Disease Risk Factors with Intracranial Arterial Blood Flow in Whites and African Americans.

Lindsay R Clark1,2,3, Derek Norton4, Sara E Berman5, Sterling C Johnson1,2,3, Barbara B Bendlin1,2, Oliver Wieben6,7, Patrick Turski6,7, Cynthia Carlsson1,2,3, Sanjay Asthana1,3, Carey E Gleason1,3, Heather M Johnson8.   

Abstract

BACKGROUND: Alzheimer's disease (AD) has a higher prevalence among African Americans. Targeting cardiovascular and metabolic risk factors may be potential mechanisms to modify AD risk and address racial/ethnic disparities in AD dementia.
OBJECTIVE: This study investigated relationships among cardiovascular and metabolic risk factors, APOE genotype, AD biomarkers, and intracranial arterial blood flow in Whites and African Americans enriched for AD risk.
METHODS: 399 cognitively unimpaired adults from the Wisconsin Alzheimer's Disease Research Center completed physical and neuroimaging examinations. A 4D Flow MRI sequence (phase-contrast vastly under sampled isotropic projection imaging) measured intracranial arterial flow in the Circle of Willis. Linear mixed-effects regression models estimated relationships between risk factors and intracranial arterial flow and tested interactions with racial group, APOE genotype, and AD biomarkers, with separate models per risk factor.
RESULTS: Higher fasting glucose was associated with lower intracranial arterial flow; no additional relationships between flow and risk factors were observed. Main effects of racial group were observed, without an interaction, indicating lower flow in African Americans compared to Whites. In race-stratified analyses, higher glucose and triglycerides were associated with lower flow for African Americans, but not for Whites. No main effects or interactions among risk factors, APOE, or AD biomarkers, and flow were observed.
CONCLUSION: Elevated fasting glucose and triglycerides were associated with lower intracranial arterial flow; these relationships were more prominent in African Americans. Targeting metabolic risk factors may impact intracranial arterial health. Additional research is needed to determine if this will impact disparities in dementia prevalence.

Entities:  

Keywords:  African Americans; Alzheimer’s disease; Apolipoprotein E4; aging; cerebrovascular circulation; glucose; metabolic syndrome; neuroimaging; risk factors

Year:  2019        PMID: 31658057      PMCID: PMC7081660          DOI: 10.3233/JAD-190645

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  41 in total

1.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons.

Authors:  Jessica B S Langbaum; Kewei Chen; Lenore J Launer; Adam S Fleisher; Wendy Lee; Xiaofen Liu; Hillary D Protas; Stephanie A Reeder; Daniel Bandy; Meixiang Yu; Richard J Caselli; Eric M Reiman
Journal:  Neurobiol Aging       Date:  2011-08-06       Impact factor: 4.673

3.  Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults.

Authors:  Siobhan M Hoscheidt; J Mikhail Kellawan; Sara E Berman; Leonardo A Rivera-Rivera; Rachel A Krause; Jennifer M Oh; Michal S Beeri; Howard A Rowley; Oliver Wieben; Cynthia M Carlsson; Sanjay Asthana; Sterling C Johnson; William G Schrage; Barbara B Bendlin
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

4.  Rates of dementia in three ethnoracial groups.

Authors:  B J Gurland; D E Wilder; R Lantigua; Y Stern; J Chen; E H Killeffer; R Mayeux
Journal:  Int J Geriatr Psychiatry       Date:  1999-06       Impact factor: 3.485

Review 5.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

6.  Correlations between cognitive impairment, middle cerebral artery flow velocity and cortical glucose metabolism in the early phase of Alzheimer's disease.

Authors:  M Franceschi; M Alberoni; S Bressi; N Canal; G Comi; F Fazio; F Grassi; D Perani; M A Volonté
Journal:  Dementia       Date:  1995 Jan-Feb

7.  Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.

Authors:  Liesi E Hebert; Jennifer Weuve; Paul A Scherr; Denis A Evans
Journal:  Neurology       Date:  2013-02-06       Impact factor: 9.910

8.  Improved 3D phase contrast MRI with off-resonance corrected dual echo VIPR.

Authors:  Kevin M Johnson; Darren P Lum; Patrick A Turski; Walter F Block; Charles A Mistretta; Oliver Wieben
Journal:  Magn Reson Med       Date:  2008-12       Impact factor: 4.668

Review 9.  Primary prevention of Alzheimer's disease: is it an attainable goal?

Authors:  Jee-Young Han; Seol-Heui Han
Journal:  J Korean Med Sci       Date:  2014-07-11       Impact factor: 2.153

10.  Defining Disease Modifying Therapy for Alzheimer's Disease.

Authors:  J Cummings; N Fox
Journal:  J Prev Alzheimers Dis       Date:  2017-04-25
View more
  4 in total

Review 1.  Neurovascular Dysfunction in Diverse Communities With Health Disparities-Contributions to Dementia and Alzheimer's Disease.

Authors:  Napatsorn Saiyasit; Evan-Angelo R Butlig; Samantha D Chaney; Miranda K Traylor; Nanako A Hawley; Ryleigh B Randall; Hanna V Bobinger; Carl A Frizell; Franklin Trimm; Errol D Crook; Mike Lin; Benjamin D Hill; Joshua L Keller; Amy R Nelson
Journal:  Front Neurosci       Date:  2022-06-29       Impact factor: 5.152

2.  Association of dyslipidaemia with Alzheimer's disease in a cohort of postmenopausal women.

Authors:  Ning Li; Xiaoying Xu; Shuai Mao; Ye Jiang; Yadong Hu; Ruowei Xing; Yajing Chen; Junxing Ye; Li Ling; Xianshang Zeng; Guowei Han
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

Review 3.  Dysregulation of Endothelin-1: Implications for Health Disparities in Alzheimer's Disease.

Authors:  Donald J Alcendor
Journal:  J Pers Med       Date:  2020-10-28

Review 4.  Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.

Authors:  Carey E Gleason; Megan Zuelsdorff; Diane C Gooding; Amy J H Kind; Adrienne L Johnson; Taryn T James; Nickolas H Lambrou; Mary F Wyman; Fred B Ketchum; Alexander Gee; Sterling C Johnson; Barbara B Bendlin; Henrik Zetterberg
Journal:  Alzheimers Dement       Date:  2021-12-06       Impact factor: 16.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.